| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| April 23, 2026 | ±2.8% | -2.6% | over-priced |
| January 29, 2026 | ±4.9% | +3.6% | over-priced |
| October 24, 2025 | ±4.2% | +2.8% | over-priced |
| April 25, 2025 | ±4.3% | +0.7% | over-priced |
| January 31, 2025 | ±5.2% | +0.4% | over-priced |
| April 29, 2024 | ±3.0% | +0.4% | over-priced |
| January 29, 2024 | ±3.4% | +0.8% | over-priced |
| October 23, 2023 | ±3.8% | -0.1% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | $1.45 | $5.8B | $1.8B |
| Q2 FY2026 | $1.26 | $5.3B | $1.6B |
| Q1 FY2026 | $1.24 | $5.3B | $1.6B |
| Q4 FY2025 | $1.34 | $5.2B | $1.7B |
Lam Research Corp (LRCX) reports in 60 days, with the next report estimated for August 12, 2026. Across the last 8 reports, options priced an average ±4.0% earnings move while the stock actually moved 1.4% on average — the market has systematically over-priced LRCX's earnings risk. Fundamentals into the print: EPS up 40.8% year-over-year, revenue up 23.8%. QuantLogix's live 5-factor engine currently reads LRCX as a strong buy at 70/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →